Literature DB >> 9784863

A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src.

Y Liu1, K Shah, F Yang, L Witucki, K M Shokat.   

Abstract

Engineered proteins with specificity for unnatural substrates or ligands are useful tools for studying or manipulating complex biological systems. We have engineered the prototypical tyrosine kinase v-Src to accept an unnatural ATP analogue N6-(benzyl) ATP in order to identify v-Src's direct cellular substrates. Here we have used molecular modeling to analyze the binding mode of N6-(benzyl) ATP. Based on this modeling we proposed that a new ATP analogue (N6-(2-phenethyl) ATP might be a better substrate than N6-(benzyl) ATP for the I338G mutant of v-Src. In fact the newly proposed analogue (N6-(2-phenethyl) ATP is a somewhat improved substrate for the engineered kinase (kcat = 0.6 min-1, KM = 8 microM). We also synthesized and screened three analogues of N6-(benzyl) ATP: N6-(2-methylbenzyl), ATP N6-(3-methylbenzyl), and ATP N6-(4-methylbenzyl) ATP to further probe the dimensions and shape of the introduced pocket. Results from screening newly synthesized ATP analogues agreed well with our modeling predictions. We conclude that rather than engineering a 'new' pocket by mutation of Ile 338 in v-Src to the smaller Ala or Gly residues, the I338G and I338A mutants possess a 'path' for the N6 substituent on ATP to gain access to an existing pocket in the ATP binding site. We expect to be able to extend the engineering of v-Src's ATP specificity to other kinase families based on our understanding of the binding modes of ATP analogues to engineered kinases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9784863     DOI: 10.1016/s0968-0896(98)00099-6

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  38 in total

Review 1.  Protein kinases: evolution of dynamic regulatory proteins.

Authors:  Susan S Taylor; Alexandr P Kornev
Journal:  Trends Biochem Sci       Date:  2010-10-23       Impact factor: 13.807

2.  A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1.

Authors:  Nicholas T Hertz; Amandine Berthet; Martin L Sos; Kurt S Thorn; Al L Burlingame; Ken Nakamura; Kevan M Shokat
Journal:  Cell       Date:  2013-08-15       Impact factor: 41.582

Review 3.  Designing selective inhibitors for calcium-dependent protein kinases in apicomplexans.

Authors:  Raymond Hui; Majida El Bakkouri; L David Sibley
Journal:  Trends Pharmacol Sci       Date:  2015-05-20       Impact factor: 14.819

4.  Structural basis for specificity of TGFβ family receptor small molecule inhibitors.

Authors:  Abiodun A Ogunjimi; Elton Zeqiraj; Derek F Ceccarelli; Frank Sicheri; Jeffrey L Wrana; Laurent David
Journal:  Cell Signal       Date:  2011-10-01       Impact factor: 4.315

Review 5.  Resolving Behavioral Output via Chemogenetic Designer Receptors Exclusively Activated by Designer Drugs.

Authors:  C Joseph Burnett; Michael J Krashes
Journal:  J Neurosci       Date:  2016-09-07       Impact factor: 6.167

Review 6.  Evolution of a dynamic molecular switch.

Authors:  Susan S Taylor; Hiruy S Meharena; Alexandr P Kornev
Journal:  IUBMB Life       Date:  2019-05-06       Impact factor: 3.885

Review 7.  The Bump-and-Hole Tactic: Expanding the Scope of Chemical Genetics.

Authors:  Kabirul Islam
Journal:  Cell Chem Biol       Date:  2018-08-02       Impact factor: 8.116

8.  The ins and outs of bcr-abl inhibition.

Authors:  E Premkumar Reddy; Aneel K Aggarwal
Journal:  Genes Cancer       Date:  2012-05

9.  Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.

Authors:  Sebastian Lourido; Chao Zhang; Michael S Lopez; Keliang Tang; Jennifer Barks; Qiuling Wang; Scott A Wildman; Kevan M Shokat; L David Sibley
Journal:  J Med Chem       Date:  2013-03-26       Impact factor: 7.446

10.  Identification of CDK2 substrates in human cell lysates.

Authors:  Yong Chi; Markus Welcker; Asli A Hizli; Jeffrey J Posakony; Ruedi Aebersold; Bruce E Clurman
Journal:  Genome Biol       Date:  2008-10-13       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.